{"classes":[{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% CI were not estimable due to insufficient number of participants and/or events.","groupId":"OG000","lowerLimit":"32.23","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants administered with daratumumab 16 mg/kg on Day 1, 8, 15, 22 (cycle 1), Days 1, 8, 15, and 22 (cycle 2), Days 1 and 15 (Cycles 3 to 6), Day 1 (Cycle 7+) along with Lenalidomide 25 milligram (mg) on Day 1 to 21 of each 28-day cycle and Dexamethasone 40 mg (weekly) and may be reduced to 20 mg (weekly after cycle 6 at the investigator's discretion). Each treatment cycle consists of 28 days.","id":"OG000","title":"Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"ITT population analysis set included all enrolled participants who signed the informed consent during Phase 2.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Phase 2: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}